Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JUN | P05412 | 1/20 | 0.57 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.57 |
| ▸ | UGT1A3 | P35503 | 1/20 | 0.57 |
| ▸ | UGT1A8 | Q9HAW9 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 7/20 | 0.35 |
| ▸ | HTR1A | P08908 | 5/20 | 0.35 |
| ▸ | DRD2 | P14416 | 5/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 2/20 | 0.34 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2963604 | 0.91 | JUN (0.53) | JUNUGT1A1UGT1A3UGT1A8LMNA | |
| SCHEMBL1100281 | 0.86 | JUN (0.64) | JUNUGT1A1UGT1A3UGT1A8LMNA | |
| SCHEMBL305411 | 0.85 | JUN (0.75) | JUNUGT1A1UGT1A3UGT1A8LMNA | |
| SCHEMBL2964477 | 0.85 | JUN (0.59) | JUNUGT1A1UGT1A3UGT1A8LMNA | |
| SCHEMBL2967854 | 0.79 | JUN (0.59) | JUNUGT1A1UGT1A3UGT1A8 | |
| SCHEMBL2965022 | 0.78 | JUN (0.61) | JUNUGT1A1UGT1A3UGT1A8LMNA | |
| SCHEMBL2960643 | 0.77 | JUN (0.56) | JUNUGT1A1UGT1A3UGT1A8LMNA | |
| SCHEMBL2967226 | 0.76 | JUN (0.69) | JUNUGT1A1UGT1A3UGT1A8LMNA | |
| SCHEMBL1108362 | 0.76 | JUN (0.65) | JUNUGT1A1UGT1A3UGT1A8LMNA | |
| SCHEMBL30754698 | 0.76 | JUN (0.55) | JUNUGT1A1UGT1A3UGT1A8LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911356-B2 | Regulation of mutant TERT by BRAF V600E/map kinase pathway through FOS/GABP in human cancer | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-02-27 | — | — | US | claimed |
| US-20200323805-A1 | REGULATION OF MUTANT TERT BY BRAF V600E/MAP KINASE PATHWAY THROUGH FOS/GABP IN HUMAN CANCER | THE JOHNS HOPKINS UNIVERSITY | 2020-10-15 | — | — | US | claimed |
| EP-2258361-B1 | USE OF BENZOPHENONE DERIVATIVE OR SALT THEREOF AND TNFalpha INHIBITOR IN COMBINATION AND PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVE OR SALT THEREOF AND THE INHIBITOR | TOYAMA CHEMICAL CO LTD (JP) | 2014-09-17 | — | — | EP | claimed |
| EP-2266557-B1 | COMBINATION OF BENZOPHENONE DERIVATIVE OR SALT THEREOF AND IMMUNOSUPPRESSING AGENT, AND PHARMACEUTICAL COMPOSITION COMPRISING THESE COMPONENTS | TOYAMA CHEMICAL CO LTD (JP) | 2013-08-14 | — | — | EP | claimed |
| US-20120046326-A1 | DRUG CONTAINING BENZOPHENONE DERIVATIVE OR ITS SALT | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-02-23 | — | — | US | claimed |
| US-20110039813-A1 | METHOD OF UTILIZATION OF COMBINATION OF BENZOPHENONE DERIVATIVE OR SALT THEREOF AND IMMUNOSUPPRESSING AGENT, AND PHARMACEUTICAL COMPOSITION COMPRISING THESE COMPONENTS | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-02-17 | — | — | US | claimed |
| US-20110020366-A1 | USE OF BENZOPHENONE DERIVATIVE OR SALT THEREOF AND TNF ALPHA INHIBITOR IN COMBINATION AND PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVE OR SALT THEREOF AND THE INHIBITOR | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-01-27 | — | — | US | claimed |
| EP-2266557-A1 | METHOD OF UTILIZATION OF COMBINATION OF BENZOPHENONE DERIVATIVE OR SALT THEREOF AND IMMUNOSUPPRESSING AGENT, AND PHARMACEUTICAL COMPOSITION COMPRISING THESE COMPONENTS | Toyama Chemical Co., Ltd. (JP) | 2010-12-29 | — | — | EP | claimed |
| EP-2258361-A1 | USE OF BENZOPHENONE DERIVATIVE OR SALT THEREOF AND TNF INHIBITOR IN COMBINATION AND PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVE OR SALT THEREOF AND THE INHIBITOR | Toyama Chemical Co., Ltd. (JP) | 2010-12-08 | — | — | EP | claimed |
| US-20100240891-A1 | DRUG CONTAINING BENZOPHENONE DERIVATIVE OR ITS SALT | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-09-23 | — | — | US | claimed |
| US-7772285-B2 | Benzophenone derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-08-10 | — | — | US | claimed |
| US-20250290152-A1 | GENETIC TRIO OF BRAF AND TERT MUTATIONS AND RS2853669TT IN PAPILLARY THYROID CANCER AGGRESSIVENESS | THE JOHNS HOPKINS UNIVERSITY | 2025-09-18 | — | — | US | disclosed |
| US-11911356-B2 | Regulation of mutant TERT by BRAF V600E/map kinase pathway through FOS/GABP in human cancer | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-02-27 | — | — | US | disclosed |
| US-20200323805-A1 | REGULATION OF MUTANT TERT BY BRAF V600E/MAP KINASE PATHWAY THROUGH FOS/GABP IN HUMAN CANCER | THE JOHNS HOPKINS UNIVERSITY | 2020-10-15 | — | — | US | disclosed |
| US-9066977-B2 | Method of utilization of combination of benzophenone derivative or salt thereof and immunosuppressing agent, and pharmaceutical composition comprising these components | TOYAMA CHEMICAL CO., LTD. (JP) | 2015-06-30 | — | — | US | disclosed |
| US-20110039813-A1 | METHOD OF UTILIZATION OF COMBINATION OF BENZOPHENONE DERIVATIVE OR SALT THEREOF AND IMMUNOSUPPRESSING AGENT, AND PHARMACEUTICAL COMPOSITION COMPRISING THESE COMPONENTS | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-02-17 | — | — | US | disclosed |
| US-20110020366-A1 | USE OF BENZOPHENONE DERIVATIVE OR SALT THEREOF AND TNF ALPHA INHIBITOR IN COMBINATION AND PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVE OR SALT THEREOF AND THE INHIBITOR | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-01-27 | — | — | US | disclosed |
| EP-2266557-A1 | METHOD OF UTILIZATION OF COMBINATION OF BENZOPHENONE DERIVATIVE OR SALT THEREOF AND IMMUNOSUPPRESSING AGENT, AND PHARMACEUTICAL COMPOSITION COMPRISING THESE COMPONENTS | Toyama Chemical Co., Ltd. (JP) | 2010-12-29 | — | — | EP | disclosed |
| EP-2258361-A1 | USE OF BENZOPHENONE DERIVATIVE OR SALT THEREOF AND TNF INHIBITOR IN COMBINATION AND PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVE OR SALT THEREOF AND THE INHIBITOR | Toyama Chemical Co., Ltd. (JP) | 2010-12-08 | — | — | EP | disclosed |
| US-20100240891-A1 | DRUG CONTAINING BENZOPHENONE DERIVATIVE OR ITS SALT | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039813-A1 | METHOD OF UTILIZATION OF COMBINATION OF BENZOPHENONE DERIVATIVE OR SALT THEREOF AND IMMUNOSUPPRESSING AGENT, AND PHARMACEUTICAL COMPOSITION COMPRISING THESE COMPONENTS | SSB, NR3C2, BRPF3 | JUN 3882/4885UGT1A1 1141/4885UGT1A3 946/4885 |
| US-20100240891-A1 | DRUG CONTAINING BENZOPHENONE DERIVATIVE OR ITS SALT | SOST, MYD88, TRAF6 | JUN 528/4885UGT1A1 3139/4885UGT1A3 3682/4885 |
| US-20110020366-A1 | USE OF BENZOPHENONE DERIVATIVE OR SALT THEREOF AND TNF ALPHA INHIBITOR IN COMBINATION AND PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVE OR SALT THEREOF AND THE INHIBITOR | TNF, NFKBIA, CHUK | JUN 1774/4885UGT1A1 2605/4885UGT1A3 3335/4885 |
| US-20120046326-A1 | DRUG CONTAINING BENZOPHENONE DERIVATIVE OR ITS SALT | SOST, MYD88, TRAF6 | JUN 528/4885UGT1A1 3139/4885UGT1A3 3682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.